The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).
 
Sarmad Sadeghi
Consulting or Advisory Role - Cardiff Oncology (I); Cardinal Health
Research Funding - Merck; Pfizer
 
Rahul Atul Parikh
Stock and Other Ownership Interests - Myovant Sciences (I)
Consulting or Advisory Role - Merck
Research Funding - Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Denice D. Tsao-Wei
No Relationships to Disclose
 
Susan G. Groshen
No Relationships to Disclose
 
Ming Li
No Relationships to Disclose
 
Leonard Joseph Appleman
Consulting or Advisory Role - AADi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Janssen Oncology; Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Surface Oncology (Inst)
Other Relationship - Pfizer
(OPTIONAL) Uncompensated Relationships - Exelixis
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
David M. Nanus
Consulting or Advisory Role - AstraZeneca; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Zenith Epigenetics (Inst)
 
Ana M. Molina
Consulting or Advisory Role - Eisai; Eisai; Eisai; Exelixis; Janssen
 
Cheryl Kefauver
No Relationships to Disclose
 
Moshe Chaim Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Aravive (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Pfizer
 
Brian I. Rini
Leadership - MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - 3D Medicines; Aravive; Arrowhead Pharmaceuticals; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; GlaxoSmithKline; Merck; Pfizer; Shionogi; Surface Oncology; synthorx
Research Funding - Aravive (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Surface Oncology (Inst); Taris (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; bristol -Myers Squibb; EMD Serono; Exelixis; Gilead Sciences; Hengrui Pharmaceutical; Hinova Pharmaceuticals; Janssen Oncology; Merck; Myovant Sciences; Myovant Sciences; Pfizer; Propella Therapeutics; Seagen; Tavanta Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Seagen (Inst)
 
David I. Quinn
Employment - Abbvie
Honoraria - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Roche
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)